NIH-funded research networks provide evidence on cabotegravir and rilpivirine in additional populations.

NIH-funded trial shows promising outcomes with treatment started promptly after birth.

NIH-funded findings inform interdisciplinary care approach across the lifespan.

Multi-country findings provide evidence on HIV prevention for a priority population.

NIH trial reveals need for more accurate screening in Black people and cisgender women.

Detailed interim results will soon be shared through scientific channels.

Human immunodeficiency virus (HIV) is an RNA (ribonucleic acid) virus that infects human immune cells, in particular CD4 T lymphocytes and is acquired through mucosal or intravenous...

NIH leadership calls for population-specific considerations in study design.

Study suggests greater CD8+ T-cell activity may increase HIV immunity.

The investigators believe their study shows that very early ART is safe and is key to suppressing HIV to undetectable levels during early childhood periods of rapid growth.